ThinkSono Raises £2.1M and Receives Key EU Regulatory Approval

ThinkSono, a leading developer in ultrasound AI technology, has successfully completed an oversubscribed funding round, raising £2.1 million ($2.7 million). This achievement brings the total funds raised by the company to approximately £5 million ($6.4 million). The funding round saw contributions from id4 ventures, Brandenburg Kapital, and several other investors, facilitating ThinkSono's ongoing mission to revolutionize medical imaging and patient care globally.

Concurrently, ThinkSono announced receiving the Class IIb CE mark for its ThinkSono Guidance system. This system empowers non-ultrasound trained healthcare workers to screen for deep vein thrombosis (DVT), a leading cause of preventable hospital death, and refer findings to specialists. This clearance exemplifies ThinkSono's commitment to enhancing health services with advanced AI technologies.

In its expansion efforts, ThinkSono disclosed forming strategic alliances with NYU Langone Health and Temple Health in the U.S. These partnerships aim to facilitate FDA approval, ushering ThinkSono's innovative solutions into the American healthcare arena.

CEO Fouad Al Noor expressed excitement over the funding and regulatory milestones, citing the potential for ThinkSono's technology to significantly advance medical imaging and improve patient outcomes. The company's technology has been highlighted as a potential solution for the longstanding challenge of efficiently screening for DVT.